Morgan Stanley raised the firm’s price target on Cardinal Health (CAH) to $166 from $142 and keeps an Overweight rating on the shares. Steady utilization has supported Core Pharma growth and the firm views Cardinal as having room for further re-rating, says the analyst, who continues to view the current time as the “Golden Era” for drug distribution.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAH:
- Cardinal Health’s Promising Growth Under New Leadership Justifies Buy Rating
- Cardinal Health price target raised to $170 from $160 at UBS
- Cardinal Health price target raised to $170 from $156 at Baird
- Cardinal Health Reports Strong Q3 Earnings and Raises Outlook
- Cardinal Health’s Strong Growth Prospects: Emphasizing Pharma and Other Segments Amid Tariff Concerns